ArticleJournal of cancer research and clinical oncology2026
Ubiquitin C-terminal hydrolase L3 promotes liver cancer cell proliferation by modulating the AMP-activated protein kinase signaling pathway.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThe deubiquitinase Ubiquitin C-Terminal Hydrolase L3 (UCHL3) is highly expressed in multiple cancer types and generally considered as an oncogene. However, its functions in liver cancer are unclear. This study investigated the role of UCHL3 in liver cancer cell growth and evaluated its potential clinical significance as a prognostic marker.
methodsThe expression of UCHL3 in cancer and its correlations with clinical parameters were assessed by using TCGA databases. Gene expression was analyzed by real time-PCR, Western Blotting, and immunostaining. Colony formation assays were performed and growth curve were measured to evaluate the function of UCHL3 in liver cancer cell proliferation. Gene Set Enrichment Analysis (GSEA) was used to explore enriched pathways.
resultsWe found that UCHL3 was essential in promoting liver cancer cell proliferation. It was highly expressed in liver cancer tissues and was a negative prognostic marker for liver cancer. Knocking down UCHL3 reduced the expression of cell cycle regulators, such as Cyclin A2, Cyclin B1 and MAD2, inhibiting cell cycle progression. The inhibition was partially due to the alteration of autophagy upon UCHL3 deprivation, as disruption of autophagy restored the protein level of Cyclin B1 and reversed cell cycle arrest. Suppressing UCHL3 was associated with the activation of AMP-activated protein kinase (AMPK) signaling pathway, which was important in controlling autophagy activation.
conclusionUCHL3 may negatively modulate the AMPK pathway and autophagy in liver cancer to maintain the expression of cell cycle regulators and facilitate cell proliferation. Targeting overexpressed UCHL3 may be feasible to inhibit liver cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.